The Biennial Renewal Obligation Under MoCRA
The Modernization of Cosmetics Regulation Act of 2022 (MoCRA) fundamentally altered the compliance landscape for cosmetics manufacturers and processors by imposing, for the first time, a mandatory facility registration regime enforced by the U.S. Food and Drug Administration. Section 607 of the Federal Food, Drug, and Cosmetic Act, as amended by MoCRA, requires that facility registrations be renewed biennially—every two years, in even-numbered years. As the industry approaches the 2026 renewal cycle, companies that registered facilities in 2024 face their first real test of this recurring compliance obligation.
Unlike the initial registration push, which was driven by a hard statutory deadline and significant industry attention, the 2026 renewal cycle will unfold with comparatively less fanfare. That reality creates genuine risk. Compliance teams that treated the 2024 registration as a one-time project, rather than the inception of an ongoing regulatory relationship with FDA, may be caught off guard by renewal deadlines, updated portal requirements, and the consequences of inaccurate or stale facility data.
Why the 2026 Cycle Matters More Than It Appears
The biennial renewal requirement is not a mere administrative formality. FDA has been explicit that registration information must remain current, and the agency has authority under MoCRA to suspend a facility's registration if it determines that a cosmetic product manufactured or processed at the facility could cause serious adverse health consequences and the responsible party fails to take appropriate corrective action. A suspended registration has severe commercial consequences: products manufactured at a facility with a suspended registration are deemed adulterated or misbranded, effectively halting interstate commerce for that facility's output.
While suspension is generally triggered by safety-related enforcement concerns rather than by a late renewal alone, the mechanics of the renewal process intersect with suspension risk in an important way. Facilities with lapsed, inaccurate, or abandoned registrations are more likely to draw FDA scrutiny, complicate any subsequent corrective action process, and lose the procedural protections that come with a well-documented compliance history. A clean, current registration is both a legal obligation and a practical shield.
The Updated Cosmetics Direct Portal
FDA's Cosmetics Direct portal, the electronic submission system built on the agency's Electronic Submissions Gateway, has undergone iterative refinements since its 2023 launch. For the 2026 renewal cycle, companies should expect continued enhancements to data validation, facility identifier verification, and cross-referencing between facility registrations and product listings. These updates are designed to reduce duplicate or orphaned entries, but they also mean that data submitted in 2024 under earlier portal configurations may need to be reviewed, reformatted, or supplemented to satisfy current field requirements.
Key portal-related action items for the 2026 cycle include:
- Confirming FDA Establishment Identifier (FEI) continuity. Ensure the FEI assigned during initial registration matches current records and has not been affected by any FDA database reconciliation.
- Reviewing responsible person and contact information. Personnel changes since 2024 must be reflected accurately; outdated contacts can delay FDA communications about deficiencies or safety inquiries.
- Verifying facility activity descriptions. If a facility's manufacturing or processing activities have changed—new product lines, expanded contract manufacturing, discontinued operations—the registration must reflect current activities, not the 2024 snapshot.
- Cross-checking linked product listings. Because product listings and facility registrations are interdependent within Cosmetics Direct, discrepancies between the two can generate flags during FDA review.
Building a Durable Renewal Compliance Process
Companies that manage multiple facilities, contract manufacturing relationships, or private label arrangements face particular complexity in the renewal cycle. A single brand owner may rely on registrations submitted by third-party manufacturers, and confirming that those registrations remain current and accurate is a shared, though not always clearly allocated, responsibility.
We recommend that clients treat the 2026 renewal not as an isolated filing task but as the trigger for an internal compliance audit. Practical steps include:
- Calendaring renewal windows well in advance of the statutory deadline, with internal milestones for data review at 90, 60, and 30 days out.
- Assigning clear internal ownership of the Cosmetics Direct account, including credential management and succession planning for personnel turnover.
- Documenting the renewal submission and retaining confirmation records as part of the company's broader MoCRA compliance file, alongside safety substantiation documentation and adverse event records.
- Auditing contract manufacturer registrations where applicable, and obtaining written confirmation that third-party facilities have completed timely renewals.
- Reassessing exemption status, since small business exemptions and certain product-category exemptions under MoCRA are subject to conditions that may have changed since initial registration.
The Strategic Value of Early Preparation
FDA enforcement priorities under MoCRA are still developing, and the agency has signaled a measured approach as the regulated industry adjusts to the new registration and listing framework. That measured posture, however, should not be mistaken for leniency toward companies that neglect the renewal cycle altogether. Facilities with accurate, timely-renewed registrations are better positioned to respond efficiently to any FDA inquiry, to demonstrate good-faith compliance in the event of a safety concern, and to avoid the reputational and commercial disruption associated with suspension proceedings.
As the 2026 renewal cycle approaches, companies should view the Cosmetics Direct portal not merely as a filing mechanism but as the ongoing record of their regulatory standing with FDA. Proactive data maintenance, clear internal accountability, and early engagement with counsel on ambiguous exemption or classification questions will position facilities to navigate this cycle—and the recurring cycles to follow—with confidence.